中国人民解放军总医院Chinese PLA General Hospital

该疾病的证据

依据官方公开数据来源筛选

1. Colorectal cancer

   Beijing 北京市

   复旦专科声誉排行榜 2023

   • General Surgery #5 https://www.fdygs.com/news2023-1.aspx

   已发表研究

   • SFRP2 Potentiates Metastasis of Colon Cancer by Enhancing Snai1 Protein Stability via USP11. Journal of cellular and molecular medicine, 2026
   • Health technology assessment of robotic surgery for rectal cancer in China: protocol for a nationally multicentre prospective cohort study. BMJ open, 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Urology #1, Otorhinolaryngology #3, Gastroenterology #4。

2. Breast cancer

   Beijing 北京市

   已发表研究

   • Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR-Positive, HER2-Negative Breast Cancer: A Retrospective Single-Centre Cohort Analysis. Cancer medicine, 2026
   • Multiplatform single-cell and spatial transcriptomics reveal sex-specific malignant states and architecture in male breast cancer. Science advances, 2026

   另有 2 项已发表研究

   PubMed 收录了 4 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

3. Lung cancer

   Beijing 北京市

   复旦专科声誉排行榜 2023

   • Respiratory Medicine #7 https://www.fdygs.com/news2023-1.aspx
   • Thoracic Surgery 获提名 https://www.fdygs.com/news2023-1.aspx

   已发表研究

   • MYBL2 promotes malignant phenotypes and M2-like macrophage polarization through CCL2 in non-small cell lung cancer. Molecular and cellular biochemistry, 2026
   • Chinese expert consensus on radiotherapy combined with immunotherapy for unresectable lung cancer (2026 Edition). Cancer letters, 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

4. Liver cancer

   Beijing 北京市

   已发表研究

   • Novel Strategies for the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Review. Journal of gastrointestinal cancer, 2026
   • Diagnostic performance of liver imaging reporting and data system ancillary features for hepatocellular carcinoma: a systematic review and evidence synthesis. Abdominal radiology (New York), 2026

   另有 3 项已发表研究

   PubMed 收录了 5 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

5. Cervical cancer

   Beijing 北京市

   复旦专科声誉排行榜 2023

   • Gynecology 获提名 https://www.fdygs.com/news2023-1.aspx

   已发表研究

   • Assessment of Factors and Trends Affecting Different Pathological Types of Cervical Cancer in China From 2013 to 2022. Cancer medicine, 2026
   • Hypoxia Response Is Associated with Reduced HPV Activity and Tumor Microenvironment Remodeling in Cervical Cancer. Genomics, proteomics & bioinformatics, 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

6. Prostate cancer

   Beijing 北京市

   复旦专科声誉排行榜 2023

   • Urology #1 https://www.fdygs.com/news2023-1.aspx

   已发表研究

   • Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China. Urologic oncology, 2026
   • Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4。

7. Thyroid cancer

   Beijing 北京市

   已发表研究

   • Efficacy and safety of ultrasound-guided thermal ablation for T1N0M0 papillary thyroid carcinoma in adolescent patients. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2026

   PubMed 收录了 1 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

8. Nasopharyngeal carcinoma

   Beijing 北京市

   复旦专科声誉排行榜 2023

   • Otorhinolaryngology #3 https://www.fdygs.com/news2023-1.aspx

   研究平台

   • 国家眼耳鼻喉疾病临床医学研究中心 https://www.most.gov.cn/tztg/201811/t20181116_142782.html

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Gastroenterology #4。

9. Esophageal cancer

   Beijing 北京市

   复旦专科声誉排行榜 2023

   • Thoracic Surgery 获提名 https://www.fdygs.com/news2023-1.aspx

   已发表研究

   • Construction of an Esophageal Cancer Prognostic Model Based on Mitochondrial Energy Metabolism-Related Genes and Mechanism of INHBA in Promoting Malignant Progression via the Smad2/3 Pathway. Biomolecules, 2026
   • Epigenetic silencing L3MBTL4 sensitizes esophageal cancer to DNA-PKcs inhibitor. Cancer biology & therapy, 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

10. Bladder cancer

    Beijing 北京市

    复旦专科声誉排行榜 2023

    • Urology #1 https://www.fdygs.com/news2023-1.aspx

    同时上榜：在复旦榜中为 General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4。

11. Pancreatic cancer

    Beijing 北京市

    复旦专科声誉排行榜 2023

    • General Surgery #5 https://www.fdygs.com/news2023-1.aspx
    • Medical Oncology 获提名 https://www.fdygs.com/news2023-1.aspx

    同时上榜：在复旦榜中为 Urology #1, Otorhinolaryngology #3, Gastroenterology #4。

12. Kidney cancer

    Beijing 北京市

    复旦专科声誉排行榜 2023

    • Urology #1 https://www.fdygs.com/news2023-1.aspx

    同时上榜：在复旦榜中为 General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4。

13. Senile cataract

    Beijing 北京市

    复旦专科声誉排行榜 2023

    • Ophthalmology 获提名 https://rank.cn-healthcare.com/fudan/specialty-reputation/year/2023/sid/4

    同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

14. Ovarian cancer

    Beijing 北京市

    复旦专科声誉排行榜 2023

    • Gynecology 获提名 https://www.fdygs.com/news2023-1.aspx

    同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。

15. Bone and soft tissue sarcoma

    Beijing 北京市

    复旦专科声誉排行榜 2023

    • Medical Oncology 获提名 https://www.fdygs.com/news2023-1.aspx

    同时上榜：在复旦榜中为 General Surgery #5, Urology #1, Otorhinolaryngology #3。